Last Posted: Nov 15, 2019
- Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer
T Mukama, et al. JAMA Oncology, November 14, 2019 - Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines
GL Gierach et al, JAMA Oncology, November 14, 2019 - Cost-utility analysis of 21-gene assay for node-positive early breast cancer.
Masucci L et al. Current oncology (Toronto, Ont.) 2019 Oct 26(5) 307-318 - Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer.
Pomponio Maria et al. Annals of surgical oncology 2019 Nov - Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer.
Zeng Yufei et al. Journal of geriatric oncology 2019 Nov - Multigene assays in early breast cancer: Insights from recent phase 3 studies.
Markopoulos C et al. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019 Oct - [What attitude to women at high risk of breast cancer?]
Livon Doriane et al. Presse medicale (Paris, France : 1983) 2019 Nov - Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
Kwon Mi Jeong et al. Archives of pharmacal research 2019 Nov - Why using genetic risk scores on embryos is wrong
E Birney blog, November 11, 2019 - Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
Elsayegh Nisreen et al. Cancer medicine 2018 7(6) 2718-2726
.png)
No hay comentarios:
Publicar un comentario